128 related articles for article (PubMed ID: 32544863)
1. Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.
Meca-Lallana V; Aguirre C; Cardeñoso L; Alarcon T; Figuerola-Tejerina A; Del Río B; Álvarez MR; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102244. PubMed ID: 32544863
[No Abstract] [Full Text] [Related]
2. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
4. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.
Lucchini M; Bianco A; Del Giacomo P; De Fino C; Nociti V; Mirabella M
Mult Scler Relat Disord; 2020 Sep; 44():102323. PubMed ID: 32593961
[TBL] [Abstract][Full Text] [Related]
5. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
6. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Ciampi E; Uribe-San-Martin R; Cárcamo C
Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203
[No Abstract] [Full Text] [Related]
7. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.
McKay KA; Piehl F; Englund S; He A; Langer-Gould A; Hillert J; Frisell T
JAMA Netw Open; 2021 Dec; 4(12):e2136697. PubMed ID: 34851401
[TBL] [Abstract][Full Text] [Related]
8. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
9. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
[No Abstract] [Full Text] [Related]
10. Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
Sastre-Garriga J; Tintoré M; Montalban X
Mult Scler; 2020 Sep; 26(10):1153-1156. PubMed ID: 32552382
[No Abstract] [Full Text] [Related]
11. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
12. Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.
Crescenzo F; Marastoni D; Bovo C; Calabrese M
Mult Scler Relat Disord; 2020 Sep; 44():102372. PubMed ID: 32650121
[TBL] [Abstract][Full Text] [Related]
13. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
15. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
16. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Rejdak K; Grieb P
Mult Scler Relat Disord; 2020 Jul; 42():102163. PubMed ID: 32388458
[TBL] [Abstract][Full Text] [Related]
17. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.
Naser Moghadasi A; Azadvari M; Sahraian MA
Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605
[No Abstract] [Full Text] [Related]
18. COVID-19 will change MS care forever - Yes.
Meca-Lallana V
Mult Scler; 2020 Sep; 26(10):1147-1148. PubMed ID: 32567486
[No Abstract] [Full Text] [Related]
19. Multiple sclerosis and COVID-19.
Mares J; Hartung HP
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):217-225. PubMed ID: 32686774
[TBL] [Abstract][Full Text] [Related]
20. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic.
Bonavita S; Tedeschi G; Atreja A; Lavorgna L
Neurol Sci; 2020 May; 41(5):1007-1009. PubMed ID: 32303856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
